Discontinued — last reported Q4 '19

Available-for-Sale Debt Securities

Current Assets

Eli Lilly Available-for-Sale Debt Securities decreased by 47.1% to $356.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 48.0%, from $685.20M to $356.00M.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ3 2018
Last reportedQ4 2019
Metric ID: afs_debt_securities

Historical Data

14 periods
 Q2 '21Q3 '21Q1 '22Q2 '22Q3 '22Q1 '23Q2 '23Q3 '23Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$502.90M$501.60M$567.10M$553.40M$622.20M$648.10M$663.60M$628.30M$650.20M$653.80M$685.20M$688.60M$673.10M$356.00M
QoQ Change—-0.3%+13.1%-2.4%+12.4%+4.2%+2.4%-5.3%+3.5%+0.6%+4.8%+0.5%-2.3%-47.1%
YoY Change———+10.0%+24.0%+14.3%+19.9%+1.0%+0.3%-1.5%+9.1%+5.9%+3.0%-48.0%
Range$356.00M – $688.60M
CAGR-10.1%
Avg YoY Growth+3.5%
Median YoY Growth+5.9%
Current Streak2 quarters decline

Frequently Asked Questions

What is Eli Lilly's available-for-sale debt securities?
Eli Lilly (LLY) reported available-for-sale debt securities of $356.00M in Q3 2025.
How has Eli Lilly's available-for-sale debt securities changed year-over-year?
Eli Lilly's available-for-sale debt securities decreased by 48.0% year-over-year, from $685.20M to $356.00M.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.